

Curriculum Vitae

Name : LEE, Chi Ho (李智豪)
Date of Birth : 28th January 1982
Marrital status : Married
Office address : Department of Medicine, Queen Mary Hospital,
102 Pokfulam Road, Pokfulam, Hong Kong
Contacts : +852 7306-9590 (Pager)
+852 9887-1566 (Mobile)
+852 2255-4385 (Office)
Email : leechihopaul@gmail.com
pchlee@hku.hk
HKMC Registration No. : M15262
Field of Interest : Endocrinology, Diabetes and Metabolism
ORCID ID : <https://orcid.org/0000-0002-7569-409X>

I. PROFESSIONAL QUALIFICATIONS

2006	M.B.B.S. (H.K.)	The University of Hong Kong
2009	M.R.C.P. (U.K.)	Royal Colleges of Physicians, United Kingdom
2013	F.H.K.C.P. (ENDO)	The Hong Kong College of Physicians
2013	F.H.K.A.M. (Med)	The Hong Kong Academy of Medicine
2014	F.H.K.C.P. (AIM)	The Hong Kong College of Physicians

II. PRESENT POSITIONS

The University of Hong Kong:

Clinical Assistant Professor, Department of Medicine

Member, Research Centre of Heart, Brain, Hormone and Healthy Aging

Queen Mary Hospital, Hospital Authority:

Honorary Specialist Endocrinologist, Department of Medicine

III. HONOURS AND POST-GRADUATE AWARDS

- 2006 Distinction in Medicine (M.B.B.S.), the University of Hong Kong
- 2013 Best Thesis Award, Gold Award of the Hong Kong College of Physicians
“A clinical and genetic study in patients with pheochromocytomas and paragangliomas in Hong Kong”
- 2017 Croucher Foundation Fellowship 2017 for overseas training at the Garvan Institute of Medical Research, Sydney, Australia
- University of Hong Kong / China Medical Board Grants 2016/2017 for overseas training at the Garvan Institute of Medical Research, Sydney, Australia

IV. POSTS HELD:

- Jul 2006 – Jun 2007 Intern, Hospital Authority
(Medicine / Paediatrics & Adolescence /
Obstetrics & Gynaecology / Surgery)
- Jul 2007 – Jun 2014 Resident, Department of Medicine, Queen Mary Hospital
- Jul 2014 – Jun 2015 Resident specialist in Endocrinology, Diabetes and Metabolism, Department of Medicine, Queen Mary Hospital
- Since Jul 2015 Clinical Assistant Professor, Department of Medicine, The University of Hong Kong

V. POST-GRADUATE TRAINING AND COURSES

- 2009 Oct Clinical Endocrinology Update of the Endocrine Society, Atlanta
- 2013 May Osteoporosis: Essentials of Densitometry, Diagnosis and Management
An International Course of the ISCD and IOF, Hong Kong

- 2014 Sept Certificate workshop in Clinical and Translational Research Methodology, Pre-congress workshop of the 16th East Meets West Symposium, Hong Kong
- 2016 July Certificate workshop in Fibroscan training, Hong Kong
- 2018 Jan Overseas training at the Garvan Institute of Medical Research, Sydney, Australia on basic science research (Animal and Lab)

VI. PUBLICATIONS

Short Articles in Regional Journals

1. Old drugs are not bad drugs. *The Hong Kong Medical Diary* 2015; 20: 6-7.
2. 2015 – A year of SGLT2 inhibitors in Hong Kong. *The Hong Kong Medical Diary* 2016; 21:16-17.
3. Medical therapy for thyrotoxicosis. *Hong Kong Journal of Ophthalmology* 2017; 21:1.
4. New-generation insulin analogue provides glucose control with reduced blood glucose variability and hypoglycaemia risk. *MIMS Doctor (October 2017)* 2017.

Original Articles in International, Externally Refereed Journals

1. Lee CH, Woo YC, Lam KSL. Fighting the health challenges of diabetes in Hong Kong: a window into Mainland China. *Am J Public Health*. 2018 (Accepted) [IF 4.380]
2. Lee CH, Cheung CY, Woo YC, Lui DTW, Yuen MMA, Fong CHY, Chow WS, Xu A, Lam KSL. Prospective associations of circulating adipocyte fatty acid-binding protein levels with risks of renal outcomes and mortality in type 2 diabetes. *Diabetologia*. 2018 (in press) [IF 6.023]
3. Lee CH, Cheung CY, Woo YC, Lui DTW, Yuen MMA, Fong CHY, Chow WS, Xu A, Lam KSL. Circulating adipocyte fatty acid-binding protein concentrations predict multiple mortality outcomes among men and women with diabetes. *Clin*

Chem. 2018; doi:10.1373/clinchem.2018.289157 (Epub ahead of print) [IF 8.636]

4. **Lee CH**, Lam KSL. Obesity-induced insulin resistance and macrophage infiltration of the adipose tissue: a vicious cycle. *J Diabetes Investig* 2018; doi: 10.1111/jdi.12918. (Epub ahead of print) [IF 3.147]
5. Yuen KW, Cheung CYY, Tang CS, Au KW, Hai JSH, **Lee CH**, Lau KK, Cheung BMY, Sham PC, Xu A, Lam KSL, Tse HF. Age-Biomarkers-Clinical (ABC) risk factors for prediction of cardiovascular events in patients with coronary artery disease. *Arterio Thromb Vasc Biol.* 2018 (In press) [IF 6.086]
6. **Lee CH**, Gu YJ, Yeung KMY, Fong CHY, Woo YC, Chow WS, Lam KSL. Dapagliflozin and empagliflozin ameliorate hepatic dysfunction among Chinese subjects with diabetes in part through glycaemic improvement. *Diabetes Ther.* 2018; 9:285-295 [IF 2.224]
7. Ma A, Mak MSY, Shih KC, Ng ALK, Tsui CKY, Cheung RKY, Lee SH, Leung H, Leung JNS, Leung JTH, Boswell MZ, Wong MTL, **Lee CH**, Jhanji V, Tong L. Association of long-term glycaemic control on tear break times and dry eye symptoms in Chinese patients with type 2 diabetes. *Clin Exp Ophthalmol.* 2018 (In Press) [IF 3.217]
8. **Lee CH**, Woo YC, Chow WS, Cheung CYY, Fong CHY, Yuen MMA, Xu A, Tse HF, Lam KSL. Role of circulating fibroblast growth factor 21 measurements in primary prevention of coronary heart disease among Chinese patients with type 2 diabetes. *J Am Heart Assoc.* 2017; 6: pii: e005344. [IF 4.450]
9. Chan GC, **Lee CH**, Kwan LP, Yip TP, Tang SC. Acute thyroiditis: An under-recognized complication of parathyroidectomy in end-stage renal failure patients with secondary hyperparathyroidism. *Nephrology.* 2017; 22:572. [IF 2.178]
10. Woo YC, **Lee CH**, Fong CHY, Tso AWK, Cheung BMY, Lam KSL. Validation of the diabetes screening tools proposed by the American Diabetes Association in an aging Chinese population. *Plos One* 2017; 12:e0184840. doi: 10.1371/journal.pone.0184840. [IF 2.766]
11. Cheung CYY, Tang CST, Xu A, **Lee CH**, Au KW, Xu L, Fong CHY, Kwok KHM,

- Chow WS, Woo YC, Yuen MMA, Cherny SS, Hai JSH, Cheung BMY, Tan KCB, Lam TH, Tse HF, Sham PC, Lam KSL. An exome-chip association analysis in Chinese reveals a functional mis-sense variant of GCKR that regulates FGF21 levels. *Diabetes* 2017; 66:1723-1728 [IF 7.273]
12. **Lee CH**, Shih AZL, Woo YC, Fong CHY, Yuen MMA, Chow WS, Lam KSL. Which creatinine-based estimated glomerular filtration rate equation best predicts all-cause mortality in Chinese subjects with type 2 diabetes? *Diab Res Clin Pract* 2017; 126: 25-29 [IF: 2.548]
13. **Lee CH**, Huang G, Chan PH, Hai JSH, Yeung CY, Fong CHY, Woo YC, Ho KL, Yiu MK, Leung F, Lau TW, Tse HF, Lam KSL, Siu DCW. Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma. *PLoS One* 2017; 12: e0171495. doi:10.1371/journal.pone.0171495 [IF: 2.766]
14. Cheung CYY, Tang CS, Xu A, **Lee CH**, Au KW, Xu L, Fong CHY, Kwok KHM, Chow WS, Woo YC, Yuen MMA, Hai JSH, Jin YL, Cheung BMY, Tan KCB, Cherny SS, Zhu F, Zhu T, Thomas GN, Cheng KK, Jiang CQ, Lam TH, Tse HF, Sham PC, Lam KSL, Exome-chip association analysis reveals an Asian-specific missense variant in PAX4 associated with type 2 diabetes in Chinese. *Diabetologia* 2017; 60:107-115 [IF: 6.023]
15. Woo YC, **Lee CH**, Fong CH, Xu A, Tso AW, Cheung BM, Lam KS. Serum fibroblast growth factor 21 is a superior biomarker to other adipokines in predicting incident diabetes. *Clin Endocrinol (Oxf)*. 2017; 86: 37-43 [IF: 3.077]
16. **Lee CH**, Shih AZ, Woo YC, Fong CH, Leung OY, Janus E, Cheung BM, Lam KS. Optimal cut-offs of Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) to identify dysglycaemia and type 2 diabetes mellitus: A 15-year prospective study in Chinese. *PLoS One* 2016; 11:e0163424. doi: 10.1371/journal.pone.0163424 [IF: 2.766]
17. Cheung CYY, Hui EYL, **Lee PCH**, Kwok KHM, Gangwani R, Li KKW, Chan JCW, Woo YC, Chow WS, Yuen MMA, Wong RLC, Fong CHY, Xu A, Wong DSH, Sham PC, Lam KSL. Impact of genetic loci identified in genome-wide association studies on diabetic retinopathy in Chinese patients with type 2 diabetes. *Invest Ophthalmol Vis Sci*. 2016; 57:5518-5524 [IF: 3.303]

18. **Lee CH**, Lam KS. Managing Non-alcoholic fatty liver disease: Challenges and Opportunities. *J Diabetes Investig* 2016; doi: 10.1111/jdi.12534. [Epub ahead of print] [IF: 3.147]
19. **Lee CH**, Woo YC, Fong CHY, Lam JKY, Cheung BMY, Lam KSL, Tan KCB. Validation of the Pooled Cohort equations in a long-term cohort study of Hong Kong Chinese. *J Clin Lipidol* 2015; 9: 640-646 [IF: 3.58]
20. **Lee CH**, Hui EYL, Woo YC, Yeung CY, Chow WS, Yuen MMA, Fong CHY, Xu A, Lam KSL. Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria. *J Clin Endocrinol Metab* 2015; 100:1368-1375 [IF: 5.789]
21. **Lee CH**, Lam KS. Biomarkers of progression in diabetic nephropathy – the past, present and future. *J Diabetes Investig* 2015; 6:247-249 [IF: 3.147]
22. Lang BH, Yu HW, Lo CY, Lee KE, Garcia-Barcelo MM, Woo YC, **Lee CH**, Wong KP, Tam PK, Lam KS. Bilateral Pheochromocytomas in MEN2A Syndrome: A Two-Institution Experience. *World J Surg* 2015; 39:2484-2491 [IF: 2.766]
23. **Lee CH**, Cheung CYY, Chow WS, Woo YC, Yeung CY, Lang BHH, Fong CHY, Kwok KHM, Chen SPL, Mak CM, Tan KCB, Lam KSL. Genetics of apparently sporadic pheochromocytoma in a Chinese population. *Horm Metab Res* 2015; 83:833-838 [IF: 2.560]
24. Woo YC, Cheung BMY, Yeung CY, **Lee CH**, Hui EYL, Fong CHY, Tso AWK, Tam S, Lam KSL. Cardiometabolic risk profile of subjects with prediabetes diagnosed by HbA1c criteria in an urban Hong Kong Chinese population over 40 years of age. *Diabet Med* 2015; 32: 1207-1211 [IF: 3.132]
25. **Lee CH**, Woo YC, Wang Y, Yeung CY, Xu A, Lam KS. Obesity, adipokines and cancer: an update. *Clin Endocrinol (Oxf)*. 2015; 83:147-156 [IF: 3.077]
26. Hui E, Yeung CY, **Lee CH**, Woo YC, Fong CH, Chow WS, Xu A, Lam KS. Elevated circulating pigment epithelium-derived factor predicts the progression of diabetic nephropathy in patients with type 2 diabetes. *J Clin Endocrinol Metab* 2014; 99:E2169-E2177 [IF: 5.789]

27. Hui E, Xu A, Chow WS, **Lee CH**, Fong HY, Cheung CW, Tse HF, Chau MT, Cheung BMY, Lam KSL. Hypoadiponectinaemia as an independent predictor for the progression of carotid atherosclerosis: a 5-year prospective study. *Metab Syndr Relat Disord* 2014; 12: 517-522 [IF: 1.744]
28. **Lee CH**, Yuen MM, Chow WS, Tso AW, Yeung CK, Chan JC, Chau CH, Lam KS. A man with blistering eruption and tuberculosis. *BMJ* 2012; 344:d8351
29. Shea YF, **Lee CH**, Gill H, Chow WS, Lam YM, Luk HM, Lam ST, Chu LW. Delayed diagnosis of 22q11.2 deletion syndrome in an adult Chinese lady. *Chin Med J* 2012; 125:2945-2947
30. Yiu KH, Jim MH, Siu CW, **Lee CH**, Yuen M, Mok M, Shea YF, Fan K, Tse HF, Chow WH. Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. *J Clin Endocrinol Metab* 2009; 94: 109-114 [IF: 5.789]

Original Articles in preparation for submission / submitted to International, Externally Refereed Journals

31. **Lee CH**, Cheung CY, Woo YC, Yuen MMA, Fong CHY, Chow WS, Lam KSL. Different high-sensitivity C-reactive protein cut-offs to predict cardiovascular and renal outcomes in type 2 diabetes: A prospective observational study. (Submitted)
32. Cheung CY*, **Lee CH***, Tang CS, Xu A, Au KW, Fong CHY, Ng KKK, Kwok KHM, Chow WS, Woo YC, Yuen MMA, Hai J, Tan KCB, Lam TH, Tse HF, Sham PC, Lam KSL. Genetic regulation of circulating pigment epithelium-derived factor (PEDF), a novel biomarker of cancer in Chinese subjects with type 2 diabetes: an exome-chip association analysis. *Co-first authors (Submitted)
33. **Lee CH**, Chan RSM, Wan HYL, Woo YC, Cheung CY, Fong CHY, Cheung BMY, Lam TH, Janus E, Woo J, Lam KSL. Dietary intake of anti-oxidant vitamins A, C and E is inversely associated with adverse cardiovascular outcomes in Chinese – A 22-years population-based prospective study. (Submitted)

VII. CONFERENCE PAPERS

International (Externally Refereed)

(* with oral presentation)

1. **Lee CH**, Chow WS, Yuen MAM, Tso AWK, Xu A, Law LSC, Cheung SCW, Chau MT, Cheung BMY, Lam KSL. Serum adiponectin levels are predictive of carotid intima-medial thickness in a 5-year community based prospective study. *The International Diabetes Federation World Diabetes Congress, Dec 2011, Dubai**
2. **Lee CH**, Chow WS, Tso AWK, Xu A, Yuen MAM, Fong CHY, Lam TH, Lo SV, Woo YC, Yeung CY, Tse HF, Cheung BMY, Lam KSL. Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: A 12-year prospective study. *The 7th International Huaxia Congress of Endocrinology, Dec 2012, Hong Kong* (Awarded best oral presentation)*
3. **Lee CH**, Hui EYL, Woo YC, Yeung CY, Chow WS, Yuen MMA, Fong CHY, Xu A, Lam KSL. Circulating adipocyte fatty acid binding protein levels predict the progression of kidney disease in Type 2 diabetes mellitus. *The International Diabetes Federation West Pacific Region Diabetes Congress, Dec 2014, Singapore**
4. Tan KCB, **Lee CH**, Woo YC, Fong CHY, Lam JKY, Cheung BMY, Lam KSL. Validation of the Pooled Cohort equations in a Hong Kong Chinese Cohort. *The 17th International Symposium on Atherosclerosis 2015, May 2015, Amsterdam, The Netherlands*
5. **Lee CH**, Woo YC, Yuen MMA, Fong CHY, Cheung BMY, Lam KSL. Obesity indices in the prediction of incident type 2 diabetes mellitus in a long- term cohort study of Hong Kong Chinese. *The International Diabetes Federation World Diabetes Congress, Dec 2015, Vancouver, Canada (Poster presentation)*
6. **Lee CH**, Chow WS, Woo YC, Fong CHY, Chan KH, Lam KSL. Glycemic control predicts the development of dementia in type 2 diabetes. *The International Diabetes Federation World Diabetes Congress, Dec 2015, Vancouver, Canada*

7. Woo YC, **Lee CH**, Fong CHY, Xu A, Tso AWK, Cheung BMY, Lam KSL. Fibroblast Growth Factor 21 as a Biomarker is Superior to Adiponectin in the Prediction of Incident Diabetes. *The Annual Scientific Meeting of the Endocrine Society, ENDO 2016, Apr 2016, Boston, USA*
8. Woo YC, Loong CH, Chau WK, Lam KYJ, Yuen MAM, **Lee CH**, Lee AC, Tan KCB. Effect of Denosumab on Bone Mineral Density in Patients with Prior Bisphosphonate Exposure. *The 16th World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Apr 2016, Malaga, Spain*
9. **Lee CH**, Woo YC, Chow WS, Fong CHY, Yuen MMA, Xu A, Lam KSL. Serum High-Sensitivity C-reactive Protein Levels are Predictive of both the Development and Progression of Nephropathy in Chinese patients with Type 2 Diabetes Mellitus. *The 17th International Congress of Endocrinology, Sep 2016, Beijing, China**
10. **Lee CH**, Shiu, SWM, Wong Y, Tan KCB. Pre-beta HDL in Type 2 Diabetes Mellitus. *The International Diabetes Federation West Pacific Region Diabetes Congress, Oct 2016, Taipei**
11. **Lee CH**, Woo YC, Chow WS, Fong CHY, Yuen MMA, Lam KSL. Serum High-Sensitivity C reactive protein level predicts Incident Cardiovascular Outcomes Among Chinese patients with type 2 diabetes with no known cardiovascular disease. *The 77th Annual Scientific Sessions of American Diabetes Association, June 2016, San Diego, USA**

Local

(* with oral presentation)

1. **Lee CH**, Law SC, Tso AWK, Tam S, Wat NMS, Cheung BMY, Lam KSL. Haemoglobin A1c is a good parameter to assess future risk of diabetes. *The Annual Scientific Meeting of Hong Kong Society of Endocrinology, Metabolism and Reproduction, Nov 2010, Hong Kong*
2. **Lee CH**, Chow WS, Yuen MAM, Xu A, Fong CHY, Chen C, Cheung SCW, Chau MT, Wat NMS, Wong RLC, Lam KSL. The association between fibroblast growth factor 21 and carotid intima media thickness. *The 7th International Symposium on*

Healthy Aging of Research Centre of Heart, Brain, Hormone & Healthy Aging, the University of Hong Kong, Mar 2012, Hong Kong

3. **Lee CH**, Chow WS, Tso AWK, Xu A, Yuen MMA, Fong CHY, Lam TH, Lo SV, Woo YC, Yeung CY, Tse HF, Cheung BMY, Lam KSL. Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: A 12-year prospective study. *The 18th Medical Research Conference of the Department of Medicine, the University of Hong Kong, Jan 2013, Hong Kong (Awarded best poster presentation)*
4. **Lee CH**, Chow WS, Lam KSL. A Clinical and Genetic Study of Subjects with Pheochromocytomas and Paragangliomas in Hong Kong. *Annual Scientific Meeting of Hong Kong Society of Endocrinology, Metabolism and Reproduction, Nov 2013, Hong Kong* (Awarded best oral presentation)*
5. **Lee CH**, Hui EYL, Woo YC, Yeung CY, Chow WS, Yuen MMA, Fong CHY, Xu A, Lam KSL. Circulating fibroblast growth factor 21 levels predict kidney disease progression in patients with early stages of diabetic nephropathy. *Annual Scientific Meeting of Hong Kong Society of Endocrinology, Metabolism and Reproduction, Nov 2014, Hong Kong* (Awarded best oral presentation)*
6. **Lee CH**, Woo YC, Chow WS, Fong CHY, Yuen MMA, Xu A, Lam KSL. Serum High-Sensitivity C-reactive Protein Levels are Predictive of both the Development and Progression of Nephropathy in Chinese patients with Type 2 Diabetes Mellitus. *The 21st Medical Research Conference of the Department of Medicine, the University of Hong Kong, Jan 2016, Hong Kong (Awarded best poster presentation)*
7. **Lee CH**, Shih AZL, Woo YC, Fong CHY, Yuen MMA, Chow WS, Lam KSL. Which creatinine-based estimated glomerular filtration rate equation best predicts all-cause mortality in Chinese subjects with type 2 diabetes? *The 22nd Medical Research Conference of the Department of Medicine, the University of Hong Kong, Jan 2017, Hong Kong (Awarded best poster presentation)*

VIII. RESEARCH GRANTS AWARDED

(* Principal Investigator)

Training and Research Assistance Scheme (TRAS):

Year	PI	Co-I	Project	Grant Period / Ref No.	Amount (HKD)
2011	*		Genetic study in patients with apparently sporadic pheochromocytoma & paraganglioma in Hong Kong 2011 - 2013	TRAS 11-07 (01/13/124)	50,000

Research Grant Council (RGC):

Year	PI	Co-I	Project	Ref No.	Amount (HKD)
2016		*	Metabolic Determinants of Fibrosis Reversal in Advanced Chronic Hepatitis B during Long-Term Nucleoside Analogue Therapy Start Date: 1/10/2016 End Date: 30/9/2019 Number of hours per week = N/A	17124916	766,864
2017		*	Effective of long-term low-frequency high-intensity interval training (HIIT) to improve body adiposity and liver fat in adults with central obesity: A randomized controlled trial Start Date: 1/1/2019 End Date: 31/12/2021 Number of hours per week = N/A	17103818	1,148,736

The Health and Medical Research Fund (HMRF):

Year	PI	Co-I	Project	Ref No.	Amount (HKD)
2016		*	Impact of Genetic Variants Identified In Genome-Wide Association Studies and Their Possible Interaction with	03144016	940,504

			Hypertension on the Risk of Diabetic Retinopathy Start Date: 1/5/2016 End Date: 30/4/2018 Number of hours per week = 2		
2017	*		Adipocyte fatty acid binding protein as a novel marker of the development of sight threatening diabetic retinopathy Start Date: 1/4/2017 End Date: 31/3/2019 Number of hours per week = 2	14150781	770,856

SK Yee Foundation:

Year	PI	Co-I	Project	Ref No.	Amount (HKD)
2017	*		Establishing an optimal genetic screening strategy for identification of germline mutation in Southern Chinese with pheochromocytoma and paraganglioma Start Date: 1/7/2018 End Date: 30/6/2020 Number of hours per week = 16	2171210	591,740

The University of Hong Kong:

Year	PI	Co-I	Project	Ref No.	Amount (HKD)
2016	*		The Role of Novel Serum Biomarkers and Dietary Pattern in Non-Alcoholic Fatty Liver Disease among Chinese patients with type 2 diabetes in Hong Kong Start Date: 1/6/2016 End Date: 31/5/2018 Number of hours per week = 16	Seed Funding Programme for Basic Research 201604159004	150,000

IX. CLINICAL TRIALS

2010	Co-I	A 76-week, worldwide, multicenter, double-blind randomized, placebo-controlled study to assess the tolerability and efficacy of anacetrapib when added to ongoing therapy with a statin in patients with hypercholesterolemia or mixed hyperlipidemia
2010	Co-I	A phase III, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI10773 (10mg and 25mg administered once daily) as add on to pre-existing antidiabetic therapy over 52 weeks in patients with type 2 diabetes mellitus and renal impairment and insufficient glycaemic control
2010	Co-I	A multicentre, randomized, double-blind, placebo-controlled phase IV trial to evaluated the effect of saxagliptin on the incidence of cardiovascular death, myocardial infarction or ischaemic stroke in patients with type 2 diabetes
2010	Co-I	A phase II randomized, placebo-controlled clinical trial to assess the safety and efficacy of Odanacatib (MK-0822-018) to reduce the risk of fracture in osteoporosis postmenopausal women treated with Vitamin D and calcium.
2012	Co-I	A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of AMG 785 in the Treatment of Postmenopausal Women With Osteoporosis
2012	Co-I	A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovascular risk
2013	Co-I	A randomized, double blind, placebo-controlled, multicentre study to assess cardiovascular outcomes following treatment with MK-3102 in subjects with type 2 diabetes mellitus.
2013	Co-I	Phase IIb study of different oral doses of BAY 96-8862 in subjects with type 2 diabetes mellitus and clinical diagnosis of diabetic nephropathy.
2014	Co-I	A phase 2, randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate the efficacy and safety of once-daily administration of a chemokine CCR2/5 receptor antagonist (PF-04634817) in adults with type 2 diabetes and overt nephropathy.
2014	Co-I	Randomized, double-blind, placebo-controlled, parallel-group study to

		assess cardiovascular outcomes following treatment with Ertugliflozin (MK-8835/PF-04971729) in subjects with Type 2 Diabetes Mellitus and established vascular disease
2014	Co-I	A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy
2015	Co-I	A Randomized, Double-Blinded Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 In Subjects with Type 2 Diabetes Mellitus (Protocol No. MK-3102-018)
2015	Co-I	A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients with Essential Hypertension and Type 2 Diabetes in Asia (AZI-P4-002)
2015	PI* (till 12/2017)	A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care
2015	PI* (till 12/2017)	A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.
2015	PI	A phase 3, randomized, double-blind, placebo-controlled, 26-week multicenter study to evaluate the efficacy and safety of ertugliflozin in Asian subjects with type 2 diabetes mellitus and inadequate glycemic control on metformin monotherapy
2016	Co-I	Prospective Observational Study Protocol B3D-MC -B026 Asia and Latin America Fracture Observational Study (ALAFOS)
2017	Co-PI* (till 12/2017)	A Randomized Study to Evaluate the Metabolic Responses of Adding Dapagliflozin versus Sitagliptin to Chinese Patients with Type 2 Diabetes Inadequately Controlled with Insulin Therapy (DISTINCTION Study)

X. INVITED LECTURES AT OVERSEAS INSTITUTES, INTERNATIONAL & REGIONAL MEETINGS

- 2011 Nov *Diabetes Made Easy. Update on Diabetes Management, a Certificate Course for Clinicians, 26-27 Nov 2011, Hong Kong*
- 2012 Mar *Current role of DPP-4 inhibitors in type 2 diabetes treatment: Who, When and How? MSD Macau Lecture, 18 Mar 2012, Macau*
- 2015 May *New trends in diabetes management. The 20th Hong Kong Medical Forum, 16-17 May 2015, Hong Kong.*
- 2015 Jul *New trends in diabetes management. 2015 Clinical Pharmacy Conference, 25 Jul 2015, Shenzhen, China*
- 2015 Sep *Metabolic syndrome in primary care settings. HKWC Structured education program, 23 Sep 2015, Hong Kong*
- 2015 Oct *Hypoglycaemia. Update on Diabetes Management, a Certificate Course for Clinicians, 31 Oct – 1 Nov 2015, Hong Kong*
- 2015 Nov *The Role of Adipokines in Cancer. 2015 International Congress on Obesity & Metabolic Syndrome, 12 – 15 Nov 2015, Seoul, Korea*
- 2015 Dec *Update on the Clinical Management of Pheochromocytoma & Paraganglioma. The 9th Huaxia Congress of Endocrinology, 12 – 13 Dec 2015, Taipei, Taiwan*
- 2016 Mar *Recent advances in diabetes management. Continuing Medical Education Talk, 18 Mar 2016, Hong Kong*
- 2016 May *Novel Therapeutics in Type 2 Diabetes: Role of SGLT2 inhibitors. The 21st Hong Kong Medical Forum, 7 – 8 May 2016, Hong Kong*
- 2016 Jun *Each Step You Take Counts in the Managing Type 2 Diabetes. The Macau AMCGM Dinner Meeting, 10 Jun 2016, Macau.*

- 2016 Jun Recent Advances in Diabetes Management. *The 3rd Kiang Wu Hospital Diabetes Seminar, 18 Jun 2016, Macau.*
- 2016 Sep Roles of circulating adipocyte fatty-acid binding protein and fibroblast growth factor 21 in the prediction of incident coronary heart disease among Chinese subjects with type 2 diabetes. *The 5th International Congress on Lipid Metabolism & Atherosclerosis (ICLA 2016), 9 – 10 Sep 2016, Seoul.*
- 2016 Oct Obesity, inflammation and diabetic kidney disease. *The International Diabetes Federation West Pacific Region Diabetes Congress, 27 – 30 Oct 2016, Taipei*
- 2016 Nov An update on diabetes and endocrine diseases. *Endocrine Course by Internship Doctors Committee, Health Bureau of Macau, 12 Nov 2016, Macau*
- 2016 Nov Osteoporosis Debate. *Update on Osteoporosis Management, a Certificate Course for Clinicians, 27 Nov 2016, Hong Kong*
- 2016 Dec Metabolic Syndrome and Prediabetes: Metabolic Syndrome. *Explore the World of Medicine Public Lecture Series 2016, 10 Dec 2016, Hong Kong*
- 2017 Mar Personalized Management of Diabetes. *The 12th International Symposium on Healthy Aging, 11 – 12 Mar 2017, Hong Kong*
- 2017 Apr Non-alcoholic Fatty Liver Disease in Diabetes: Perspectives from an Endocrinologist. *A to Z Symposium, Diabetes Division, Hong Kong Society of Endocrinology, Metabolism and Reproduction, 14 Apr 2017, Hong Kong*
- 2017 Oct Adipocyte fatty acid binding protein, diabetic complications and mortality. *12th Asia Pacific Diabetes & Obesity Symposium (APDO), 21-22 Oct 2017, Hong Kong*

2017 Nov Non-alcoholic Fatty Liver Disease in Diabetes; and Living with Diabetes; *Update on Diabetes Management 2017, 14 Oct and 26 Nov 2017, Hong Kong*

XI. TEACHING

Undergraduate Teaching

Since 2011 MBBS II/III Clinical skills sessions (Endocrinology block)

Since 2015 MBBS IV to VI

Post-Graduate Teaching

2014 Jul Practical aspects of insulin therapy. *Endocrine module, Post-graduate Diploma Course in Diagnosis and Therapeutics in Internal Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 6 Jul 2014*

2016 Jul Practical aspects of insulin therapy. *Endocrine module, Post-graduate Diploma Course in Diagnosis and Therapeutics in Internal Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 2 - 3 Jul 2016*

2016 Jul Complications of Thyroid Disease. *Endocrine module, Post-graduate Diploma Course in Diagnosis and Therapeutics in Internal Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 2 - 3 Jul 2016*

XII. KNOWLEDGE EXCHANGE

2016 Dec Metabolic Syndrome and Prediabetes: Metabolic Syndrome. *Explore the World of Medicine Public Lecture Series 2016, 10 Dec 2016, Hong Kong*

2017 May “Eyes on Diabetes”. *Diabetes Hong Kong, 14 May 2017, Hong Kong*

2017 Jul Column about “Endocrine Hypertension” on AM730, Hong Kong

2017 Sep Column about “Fatty liver in Diabetes” on Diabetes Hong Kong Journal

2017 Nov Patient sharing on Diabetes Management, Hong Kong

2017 Dec “Vegetarian Diet in Diabetes” on RTHK TV

XIII. OTHERS

Organizer of International or Regional Meetings

- 2015 Member, Program organizing committee, the 11th International Symposium of Healthy Aging, 12-13 Mar 2016, Hong Kong
- 2015 Member, Program organizing committee, the 21st Hong Kong Medical Forum, 7 – 8 May 2016, Hong Kong
- 2016 Member, Program organizing committee, the 22nd Hong Kong Medical Forum, 13 – 14 May 2017, Hong Kong
- 2017 Chairman, Organizing committee, Update in Diabetes Management 2017, 14 – 15 Oct 2017, Hong Kong
- 2018 Member, Program organizing committee, Endocrinology, Diabetes and Metabolism Hong Kong (EDMHK) 2018, 18 Nov 2018, Hong Kong
- 2018 Chairman, Organizing Committee, the 14th International Symposium of Healthy Aging, 16-17 Mar 2019, Hong Kong

Member / Office Bearer of Academic Societies

Member, the Hong Kong Society of Endocrinology, Metabolism and Reproduction

XIV. NARRATIVE BIO

<http://press.endocrine.org/page/jcem/focusdiabetes/14-2235>